Overview

A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare LY2605541 and insulin glargine using the following measures after participants have been treated for 26 weeks: - Change in participants' overall blood sugar control - The rate of night time low blood sugar episodes - The number of participants that reach blood sugar targets without low blood sugar episodes at night - The rate of low blood sugar episodes reported over a 24-hour period
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Boehringer Ingelheim
Treatments:
Hypoglycemic Agents
Insulin
Insulin Glargine
Insulin, Globin Zinc